Daily Stock Analysis, HEDJ, HEMISPHERX BIOPHARMA INC, priceseries

HEMISPHERX BIOPHARMA INC. Daily Stock Analysis
Stock Information
Open
69.91
Close
70.06
High
70.12
Low
69.88
Previous Close
69.82
Daily Price Gain
0.24
YTD High
70.43
YTD High Date
Nov 12, 2019
YTD Low
54.75
YTD Low Date
Jan 3, 2019
YTD Price Change
14.41
YTD Gain
25.90%
52 Week High
70.43
52 Week High Date
Nov 12, 2019
52 Week Low
53.55
52 Week Low Date
Dec 26, 2018
52 Week Price Change
11.04
52 Week Gain
18.71%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Dec 6. 2016
51.29
Jan 12. 2017
53.98
25 Trading Days
5.23%
Link
Company Information
Stock Symbol
HEDJ
Exchange
NYSE
Company URL
http://www.hemispherx.net
Company Phone
215-988-0080
CEO
Thomas Kenwood Equels
Headquarters
Pennsylvania
Business Address
1617 JFK BLVD, SUITE #500, ONE PENN CENTER, PHILADELPHIA, PA 19103
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0000946644
About

Hemispherx Biopharma, Inc. is a biopharmaceutical company, which engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based disorders. Its products include Alferon N Injection and the experimental immunotherapeutic/antiviral Ampligen. Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. Ampligen includes application as a treatment for Chronic Fatigue Syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Philadelphia, PA.

Description

Hemispherx Biopharma, Inc., a specialty pharmaceutical company, engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company's primary products comprise Ampligen, an experimental drug, which is under clinical development for the treatment of chronic fatigue syndrome, Hepatitis B, HIV, renal cell carcinoma, and malignant melanoma; and Alferon N Injection, an injectable formulation of natural alpha interferon for the treatment of certain categories of genital warts. It is also developing Alferon LDO, a low-dose oral liquid formulation of natural alpha interferon for the treatment of pandemic influenza, seasonal influenza, and other emerging viruses. The company has a strategic alliance with Bioclones (Pty) Ltd. to develop various projects. Hemispherx Biopharma, Inc. was founded in 1990 and is headquartered in Philadelphia, Pennsylvania.